Johnson & Johnson (NYSE:JNJ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 10:45 AM ET
Company Participants
Joaquin Duato - CEO & Chairman
John Reed - Head of Pharma R&D
Conference Call Participants
Terence Flynn - Morgan Stanley
Terence Flynn
Great. All right. Thanks for joining us, everybody. I'm Terence Flynn, the U.S. large cap biopharma analyst. Very pleased to be hosting Johnson & Johnson this morning. For important disclosures, please see the Morgan Stanley Research disclosure website at www.morganstanley.com/researchdisclosures.
Very pleased to be hosting Joaquin Duato, who is the company's CEO and Chairman; and John Reed, who is Head of Pharma R&D. Thank you both for joining us. And Joaquin was just -- we were just chatting this is his 35th anniversary at Johnson & Johnson, so a pretty big milestone. Congratulations on that. That's been a great run. And I know you have a lot more to do here in the CEO role on the forward.
I guess I'm turning it over to you guys, if you want to make any prepared remarks before we go into questions or we can go right into questions, whatever works for you.
Joaquin Duato
No, let's go right into questions.
Question-and-Answer Session
Q - Terence Flynn
All right. Well, let's do it. Maybe obviously, there's been a lot of focus on kind of longer-term outlook. So as you think about kind of the near-term growth target that you've given for next year in terms of 3%, maybe just help us think about that.
And then confidence level in continuing that growth where, again, you guys have targeted for each of your business segments at above industry growth for each of the Pharma segment and the MedTech business. I know there are a lot of puts and takes as you think about that
- Read more current JNJ analysis and news
- View all earnings call transcripts